Vytorin Indications/Uses

Prevention of Cardiovascular Disease: Ezetimibe/Simvastatin (VYTORIN) is indicated to reduce the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization), in patients with coronary heart disease (CHD).
Prevention of Major Cardiovascular Events in Chronic Kidney Disease (CKD): Ezetimibe/Simvastatin (VYTORIN) is indicated to reduce the risk of major cardiovascular events (nonfatal myocardial infarction or cardiac death, stroke, or any revascularization procedure) in patients with chronic kidney disease.
Primary Hypercholesterolemia: Ezetimibe/Simvastatin (VYTORIN) is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolemia or mixed hyperlipidemia.
Fenofibrate can be added to Ezetimibe/Simvastatin (VYTORIN) in adult patients with mixed hyperlipidemia who require further reduction in TG and non-HDL-C and increase in HDL-C.
Homozygous Familial Hypercholesterolemia (HoFH): Ezetimibe/Simvastatin (VYTORIN) is indicated for the reduction of elevated total-C and LDL-C levels in adult and adolescent (10 to 17 years of age) patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).